CommercialCoverageMedium impact
08.00.74y, Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors
Independence Blue Cross·Ophthalmology, Pharmacy·Pharmacy
Effective date
Apr 1, 2025
We identified it
Jun 19, 2026
Summary
This is a new pharmacy policy (effective 04/01/2025) establishing coverage guidelines for intravitreal injections of VEGF antagonists, VEGF biosimilars, and combination VEGF/Ang-2 inhibitors used in ophthalmology. The billing team must review the complete policy text to identify specific prior authorization requirements, covered medications, dosing limits, and any billing code restrictions that may affect claim submission and reimbursement.
Action Required
By 04/01/2025: Billing team must obtain and review the full policy text at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=04&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-00-74y to identify: (1) specific HCPCS codes for covered intravitreal medications (likely J-codes); (2) prior authorization requirements and submission process; (3) any quantity limits or frequency restrictions; (4) documentation requirements for medical necessity. Update billing software, claims submission protocols, and provider encounter templates accordingly. Communicate requirements to ophthalmology providers and injection staff. Failure to comply with prior authorization or coverage limitations will result in claim denials or payment delays.